**Biogen Scheduled to Report Q1 2026 Results on April 29**
Biogen Inc. (NASDAQ: BIIB) will release its first-quarter 2026 financial results on April 29 before the market opens. The company’s earnings for the last quarter surpassed expectations by 23.6%, with the Zacks Consensus Estimate for Q1 sales projected at $2.25 billion and earnings at $2.96 per share.
Key factors influencing Biogen’s results include decreased sales for multiple sclerosis (MS) drugs due to competition, with Tecfidera sales estimated at $111 million and Tysabri at $359 million. Conversely, Vumerity’s sales are anticipated to rise to $164 million, aided by enhanced demand and affordability in the U.S. The company is also expected to see growth in sales from its newly launched drugs, Skyclarys and Zurzuvae. Additionally, Biogen’s collaboration revenue from the Alzheimer’s drug Leqembi is projected to continue growing. As of March, Biogen announced plans to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expected to contribute significantly to the company’s future growth.
